Understanding HIV Resistance to Entry Inhibitors to Advance the Development of Novel Antivirals

了解艾滋病毒对进入抑制剂的耐药性以促进新型抗病毒药物的开发

• 批准号: nhmrc : 1126740
• 负责人: A/Pr Paul Ramsland
• 金额: $ 59.92万
• 依托单位: RMIT University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/understanding-hiv-resistance-novel-antivirals/947848
• 关键词: Understanding; HIV; Resistance; Entry; Inhibitors

We cannot afford to be complacent in the search for improved anti HIV drugs for 2 principal reasons; First, worldwide a staggering 66% of infected individuals who need treatment are still unable to access therapy; and Second, the main reason why most treated patients are now living longer and more healthy lives is because we have never stopped developing newer therapies to provide options for patients. In this study we will develop and test newer drugs that block HIV infection of cells.

我们不能自满地寻找改进的抗艾滋病毒药物，主要有两个原因：第一，全世界有66%的需要治疗的感染者仍然无法获得治疗;第二，大多数接受治疗的患者现在活得更长，更健康的主要原因是因为我们从未停止开发新的治疗方法，为患者提供选择。在这项研究中，我们将开发和测试阻断HIV感染细胞的新药。